Article
Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid <i>in vivo</i> functional genomics
2019-03-26
Abstract excerpt
Patient-derived xenografts (PDXs) constitute a powerful set of preclinical models for in vivo cancer research, reflecting the spectrum of genomic alterations and therapeutic liabilities of human cancers 1-4 . In contrast to either cancer cell lines or genetically engineered mouse models, the utility of PDXs has been limited by the inability to perform targeted genome editing of these tumors. To address this limi...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- cbb6934f-7ff2-5c23-96f5-c4e75c9643b5
- DOI
- 10.1101/588921
